Device Trial Radar · NCT07322913
Intervascular Post-Market Clinical Follow-Up (PMCF) Registry
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- IntervascularNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 7, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this registry is to evaluate the long-term safety and performance of Intervascular Vascular Grafts and Patches (Intergard Standard, Hemashield, Intergard Silver, Intergard Synergy) for bypass, repair or replacement of aortic, peripheral, or carotid arteries. This registry is intended to further define the expected product lifetime of the devices and to collect data related to usefulness of the antimicrobial coatings.
Conditions
- Carotid Artery Diseases
- Aortic Diseases
- Peripheral Arterial Diseases
Interventions
Intergard Standard - Collagen Coated Vascular Grafts and PatchesDevice
Intergard Standard, Collagen coated vascular grafts and patches are made of knitted (knitted or knitted ultrathin) or woven polyester. The products are coated with a highly purified form of cross-linked bovine collagen to minimize intraoperative bleeding and eliminate the need for preclotting at the time of implant. Note that the radially supported grafts have a polypropylene supportive coil designed to resist kinking and compression of extra-anatomical vascular repair, where potential unwanted mechanical compression of the graft may occur.
Hemashield - Collagen Coated Vascular Grafts and PatchesDevice
Hemashield Vascular Grafts and Patches are made of knitted or woven polyester. The products are impregnated with a highly purified bovine collagen to reduce bleeding at the time of implant and thereby eliminates the operative preclotting step.
Intergard Silver - Antimicrobial Collagen Coated Vascular Grafts and PatchesDevice
Intergard Silver antimicrobial collagen coated vascular grafts are made of knitted (knitted or knitted ultrathin) or woven polyester. The Hemapatch Silver Ultrathin is a surgical patch made from knitted ultrathin polyester fabric. The products are coated with a highly purified form of cross-linked bovine collagen to minimize intraoperative bleeding and eliminate the need for preclotting at the time of implant. In addition to collagen coating, the collagen matrix of Intergard Silver vascular grafts and patches is loaded with an antimicrobial agent: silver acetate. The coating of silver is designed to inhibit the microbial colonization on the device and within tissue immediately proximate to the device in the acute post-operative phase.
Intergard Synergy - Antimicrobial Collagen Coated Vascular GraftsDevice
Intergard Synergy antimicrobial collagen coated vascular grafts are made of knitted (knitted or knitted ultrathin) polyester. The products are coated with a highly purified form of cross-linked bovine collagen to minimize intraoperative bleeding and eliminate the need for preclotting at the time of implant. In addition to collagen coating, the collagen matrix of Intergard Synergy Antimicrobial collagen coated vascular grafts is loaded with antimicrobial agents: silver acetate and triclosan. The addition of silver acetate and triclosan on collagen coated vascular products is designed to inhibit the microbial colonization on the device and in the surrounding tissues in the acute postoperative phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peripheral Arterial Disease Cohort: Cohort: Percentage of participants meeting primary device patencyTime frame: Procedure/surgery through registry completion, anticipated average of 5 years
- Aortic Disease Cohort: Percentage of participants meeting primary device patencyTime frame: Procedure/surgery through registry completion, anticipated average of 5 years
- Carotid Artery Disease Cohort: Percentage of participants achieving freedom from occlusion or reinterventionTime frame: Procedure/surgery through registry completion, anticipated average of 5 years
4 more outcomes with a free account
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
The Pennsylvania State University and The Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.